Bernard K. Ham, Senior Foreign Attorney at Dentons Lee, was invited to speak at a webinar hosted by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) on strategies for entering the U.S. bio market. In his presentation, titled “Developing Tailored Strategies for the U.S. Market,” Mr. Ham addressed the increasing challenges posed by recent U.S. policy shifts, including heightened import tariffs, drug pricing reforms, and localization requirements. He emphasized the importance of early legal and commercial planning for Korean companies seeking entry into the U.S. market.

Mr. Ham advised that companies carefully consider whether a corporation or a limited liability company (LLC) is more suitable for their needs, noting the significance of sufficient capitalization, board-centered governance, and transparent documentation with the Korean headquarters. He further stressed that commercialization strategies should be developed from the early stages of clinical development to enable agile responses to local market demands.

Mr. Ham began his legal career at the U.S. Department of Health and Human Services and has since worked at major international law firms as well as in the molecular diagnostics industry. Drawing on this experience, he now advises Korean companies across a wide range of industries on U.S. market entry, investment structuring, and cross-border legal strategy.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com